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Abstract
Purpose: A radio-guided surgery technique with β−-emitting radio-
tracers was suggested to overcome the effect of the large penetration of
γ radiation. The feasibility studies in the case of brain tumors and ab-
dominal neuro-endocrine tumors were based on simulations starting from
PET images with several underlying assumptions. This paper reports, as
proof-of-principle of this technique, an ex-vivo test on a meningioma pa-
tient. This test allowed to validate the whole chain, from the evaluation
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of the SUV of the tumor, to the assumptions on the bio-distribution and
the signal detection.
Methods: A patient affected by meningioma was administered 300 MBq
of 90Y-DOTATOC. Several samples extracted from the meningioma and
the nearby Dura Mater were analyzed with a β− probe designed specifi-
cally for this radio-guided surgery technique. The observed signals were
compared both with the evaluation from the histology and with the Monte
Carlo simulation.
Results: we obtained a large signal on the bulk tumor (105 cps)
and a significant signal on residuals of ∼0.2 ml (28 cps). We also show
that simulations predict correctly the observed yields and this allows us
to estimate that the healthy tissues would return negligible signals (≈
1 cps). This test also demonstrated that the exposure of the medical
staff is negligible and that among the biological wastes only urine has a
significant activity.
Conclusions: This proof-of-principle test on a patient assessed that
the technique is feasible with negligible background to medical personnel
and confirmed that the expectations obtained with Monte Carlo simula-
tions starting from diagnostic PET images are correct.
Keywords: radio-guided-surgery, brain tumors, β− decays, intraoperative
imaging
Introduction
Radio-guided surgery (RGS) is a technique aimed at assisting the surgeon to
reach as complete a resection of the tumoral lesion as possible, while minimizing
the amount of healthy tissue removed [1]. Before surgery, the patient is admin-
istered with a specific radio-labeled tracer that is preferentially localized in the
tumor and a probe (for a review see [2]), sensitive to the signal emitted by the
tracer, is used to identify the position of the targeted tumoral cells. As a result,
RGS provides the surgeon with real-time information about the location and
the extent of the lesion, as well as the identification of tumor margins.
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To date, established methods make use of a γ-emitting tracer and a γ radia-
tion detecting probe [3, 4] or a portable gamma camera [5, 6]. Since γ radiation
can travel through large amounts of tissue, any uptake of the tracer in nearby
healthy tissue represents a non-negligible background, strongly limiting and of-
ten preventing the use of this technique.
To overcome these limits and extend the range of applicability of RGS, it
was suggested [7] to use instead pure β−-emitting radio-isotopes. β− radiation
indeed is characterized by a penetration of only few millimeters of tissue with
essentially no γ contamination, since the Bremsstrahlung contribution, that has
a 0.1% emission probability above 100 keV, can be considered negligible. More-
over, a previous study showed that this probe sensitivity to Bremsstrahlung
photons is lower than 1% [8]. This novel approach allows to develop a handy
and compact probe which, detecting electrons and operating with low radiation
background, provides a clearer delineation of the margins of lesioned tissues. For
such reasons, a smaller injected activity is required to detect tumor residuals
compared to traditional RGS approaches. This also implies that the radiation
exposure for the medical personnel becomes almost negligible [7].
To explore the applicability of this technique several studies have been per-
formed where the expected signal from the probe prototypes was estimated
on the basis of a simulation and tests on phantoms. As a start, the clinical
cases were limited to the tumors known to express receptors to a β− emit-
ting radio-tracer, in particular the 90Y-labeled [1,4,7,10-tetraazacyclododecane-
N,N′,N′′,N′′′-tetraacetic acid0-D-Phe1,Tyr3]octreotide (DOTATOC): brain tu-
mors (meningioma and glioma) [9] and neuro-endocrine tumors [10]. In all cases
the expected tumor-non-tumor ratios were high enough to allow a detection of
0.1 ml residuals within few seconds of application of the probe.
These studies started from PET images with 68Ga-labeled DOTATOC and,
assuming that the bio-distribution of the tracer did not change when labeled
with 90Y, with a simulation program (FLUKA [11]) estimated the signal rate on
the probe. The relationship between the specific activity in tumor and healthy
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tissues and the probe counts was tuned by measuring the response of the probe
to sealed 90Y sources.
This paper reports of a first ex-vivo test that, albeit missing statistical sig-
nificance for clinical conclusions, represents a proof-of-principle for this inno-
vative technique, by showing the validity of the underlying assumptions and
by strengthening the feasibility studies. In this test the patient was injected
with 90Y-labeled DOTATOC prior to surgery and a prototype of the probe was
exposed to the radiation of the samples extracted surgically to estimate the
sensitivity of the device.
MATERIALS AND METHODS
Patient Treatment Protocol
As a proof-of-principle test meningioma patients were chosen because of the
well known high receptivity of meningioma to somatostatin analogue, such as
DOTATOC [12]. A 68 years female patient with radiological diagnosis of menin-
gioma was selected for the present study. She gave written informed consent
to participate in the clinical trial approved by IEO Ethic Committee (institu-
tional review board). To assess the in-vivo presence of somatostatin receptors,
a PET scan with 68Ga-DOTATOC was performed two weeks prior to the surgi-
cal intervention. The scan, performed one hour after the injection of 255 MBq
(4 MBq/kg of patient weight), revealed that the bulk tumor had an average
SUV∼2.3 and a volume of ∼4.1 ml. Although on meningioma there could be
larger SUVs (reaching also values > 6, see Ref. [9]), the uptake was rated suf-
ficient to test the technique, in particular in an ex-vivo (i.e. background free)
environment.
Twenty-four hours before surgical intervention, the patient was injected with
300 MBq of 90Y-DOTATOC. Before surgery the probe was placed in proximity
to the skin of the patient in several spots to estimate the level of background.
After surgery, that was performed as routine clinical indicated, the extracted
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tumor and the attached dura were sectioned in 7 samples, described in Tab. 1
and shown in Fig. 1.
Each of the samples were placed in a Petri capsule and weighted with a
precision scale. The measured weights, after subtraction of the holder weight,
are converted into a volume assuming a density of 1 g/ml and reported in
Tab. 1. These volumes suffer from significant uncertainties due to the presence
of saline solution on the samples, necessary to preserve them, and because of
the assumption on the density.
The lateral dimensions and shape of each specimen were evaluated framing
with a microscope the samples put over a graph paper. The probe was then put
in contact with each sample to measure its activity. To avoid contamination of
the probe (that proved inexistent) a thin plastic layer was interposed between
the sample and the probe. Such configuration is also consistent with the ex-
pected mode of operation, since a shielding will be needed to ensure a sterile
surgical environment.
Finally, the specimens underwent histology to evaluate their actual tumoral
nature. At the same time we measured the probe response also to samples of
urine and blood.
The Probe Prototype
In the probe prototype used in this test (visible in Fig. 2) the radiation sensitive
element is a 5 mm in diameter and 3 mm in height scintillator tip made of com-
mercial mono-crystalline para-terphenyl doped to 0.1% in mass with diphenylbu-
tadiene. This material was adopted, after a detailed study [13], due to its high
light yield (∼3 times larger than typical organic scintillators), non-hygroscopic
property, and low density that minimizes the sensitivity to photons.
The scintillator tip is enclosed by a black ABS (Acrilonitrile Butadiene
Stirene) ring with external diameter of 12 mm that shields it against radia-
tion coming from the sides. A 15 µm-thick aluminum front-end sheet covers
the detector window to ensure light sealing. The scintillator light is read by a
5
SiPM (sensL B-series 10035) biassed with 24.5 V, spectral range 300-800 nm and
peak wavelength 420 nm. This assembly is encapsulated in an easy-to-handle
aluminum cylindrical body (diameter 12 mm and length 14 cm). A portable
electronics based on Arduino Due, with wireless connection to PC or tablet was
used for the read out [14].
Laboratory tests with a 90Sr source, following the procedure described in
Ref. [15] allowed to conclude that the probe is sensitive, with an efficiency within
the acceptance greater than ≈ 50%, to electrons above ∼475 keV.
Expected rates
All previous estimates of the effectiveness of the RGS technique [9, 10] based the
conversion from the 68Ga-DOTATOC PET scan and the expected probe rates
on a full simulation with the FLUKA [11] Monte Carlo software, that included
all interactions of particles with matter. To evaluate the expected rates on
tissue samples, data from pre-operative PET scans were used, assuming that
substituting 68Ga with 90Y does not alter the biodistribution, accounting for
the difference in lifetime of the two radio-isotopes, and neglecting the expected
increase in uptake 24 hours after administration. From these data, we could
estimate the activity of the tumor at the time of the surgical intervention to be
8.1 kBq/ml. This information was used to estimate an expected signal rate on
the tumor bulk of 115 cps. The same simulation returned that in proximity of
the skin the probe should measure ∼15 cps, while in contact with the brain, i.e.
in the healthy regions close to brain tumors, only ∼1 cps, due to the blood-brain
barrier.
As far as the simulation of the samples extracted during the operation is
concerned, the most delicate part was the reconstruction in the simulation of
the shapes of the samples, that was approximated to the best that could be
done from the picture of the samples, using as reference the graph paper un-
derneath. However, this procedure does not take into account that the pressure
of the probe on the sample might have reduced its thickness. Furthermore, the
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measurement of the volume, as described above, are affected by large uncer-
tainties. Therefore the estimate of the rates on the tumor samples other than
the bulk suffer from large systematic errors and will therefore not be attempted
this time. Future experiments will have to ensure a more accurate volume and
shape measurements to be more quantitative on the small tumor residuals.
Due to the thinness of the Dura Mater(<1 mm) a separate study was devoted
to the evaluation of the uptake in the corresponding samples (labelled A and
E). A direct extraction made considering a region of interest in the DICOM
image was impossible due to the much larger PET resolution (σPET ∼3 mm).
A set of lines crossing the Dura Mater close to the tumor and including both
the healthy brain, the skull and the head skin were drawn on the PET image
as shown in the top of Fig. 3. The profile of the measured specific activity in
the voxels along each line is shown in the center plot of Fig. 3: when the line
approaches the tumor a structure around voxel # 4 raises. It corresponds to
an area of uptake between the skin and the one of the tumor, where the Dura
Mater is expected to be. Also this structure has a width compatible with the
PET resolution and it is therefore compatible with a structure much thinner
than σPET ∼3 mm. Subtracting each profile with the one from the line most
distant from the tumor, it is possible to evaluate the integral of the observed
structure, thus estimating the specific activity of the area of the Dura Mater.
Such measurements are shown in the bottom plot of Fig. 3, suggesting that
the Dura Mater is infiltrated up to about 1 cm from the tumor, with a specific
activity ∼400 Bq/mL. Since the thickness of the Dura Mater (TD) is unknown,
but it is small enough to affect significantly the expected rate on the probe for
fixed specific activity(AD), several simulation with different values of TD were
performed to estimate the relation between the two (AD vs TD, see Fig. 4) .
Dosimetry and Exposure Measurement
All wastes and the patient urine pack were kept in plexiglas boxes 1 cm thick,
able to shield radiations. Since one of the key points of this technique is the low
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exposure of the medical personnel, film badge personal dosimeters commonly
used for monitoring cumulative radiation dose were distributed to the staff. Our
dosimeters where AGFA Personal Monitoring consisting of a double-coated, low
speed, high contrast X-ray film and a double-coated, very sensitive, high con-
trast X-ray film specifically designed for recording X-γ and β radiation. This
film combination covers the measurement range from 0.1 mSv up to 1 Sv. The
film-badge personal dosimeters were worn on the outside of clothing, around the
chest or torso to represent dose to the whole body. Some film badge dosimeters
were employed to measure the ambient equivalent dose (two of these were placed
in proximity of the urine pack). In addition, in order to estimate the dose to
the hands the surgeon and the anesthetist were provided a washable bracelet
embedding a LiF thermoluminescent dosimeter (TLD), while biologists, respon-
sible for histological analysis, were provided a TLD finger ring dosimeter. The
exposure induced by the patient and the biological samples was estimated by
means of a Fluke 451B Ion Chamber Survey Meter with beta radiation slide.
Also a portable Geiger counter (Mini Monitor series 900) was employed for
contamination measurements.
RESULTS
The rates from the healthy tissues were estimated with measurements, each last-
ing 10 s, made with the probe prototype in proximity to the skin of the patient.
The average over four measurements close to an arm, a leg, the head on the
same and the opposite side of the meningioma, was 12.3 cps, in agreement with
simulations that predicted ∼15 cps. The four measurements showed variations
among the spots consistent with statistical fluctuations.
Tab. 1 reports the rates measured with the probe in each sample extracted
during surgery. The observed rate on the bulk tumor is consistent with the ex-
pectation: sample D yields 105 cps with an expectation of ∼ 115 cps. The rate
drops by a factor 2 when selecting the margins and a factor 3 when considering
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thin and small residuals. Albeit these results cannot be reliably compared with
simulation because of an excessive dependence on the residual shape, it can be
noted that also in the worst case the rate on tumor samples is 27.7 cps, signifi-
cantly higher than the nearby Dura (3.5-5 cps) and healthy brain (∼ 1 cps).
As discussed above, the rate expected on the Dura Mater samples (A and E)
crucially depends on their thickness, as reported in Fig. 4. In it, the measured
rates of 3.5-5 cps result in a sample thickness between ∼500-800 µm, that is in
good agreement with what we would expect for the Dura.
The histology, whose results are also shown in Tab. 1, confirmed that all the
samples were of tumoral nature, including the Dura samples A and E, which
showed infiltration of malignant cells. Due to technical problems, however, a
histological quantification of these infiltrations was not feasible, making it im-
possible to evaluate within this first ex-vivo test the minimal amount of tumoral
cells to which the probe is sensitive.
The tests on the other biological samples showed that blood yielded a very
low rate (3 cps on average) while the activity of the urine is important (the
measured rate was ∼150 cps, corresponding to a specific activity ∼10 kBq/ml).
As far as the exposure of the medical personnel is concerned, a Victoreen
450P gamma camera measured 0.80 (0.19) µSv/hr 10 (100) cm from the ab-
domen of the patient 5 hour after injection (and 18 before the surgical interven-
tion). The same device did not detect any significant radiation in the surgical
room or in the wastes after the intervention, apart from the urine pack that
was anyhow shielded by a 1 cm thick plexiglas box. The readings of all personal
dosimeters (Hp(10)) were consistent with zero, meaning that the operators effec-
tive doses and the equivalent dose to hands were less than dosimeters threshold
dose (40 µSv). Also the ambient dose equivalent (H*(10)) was negligible for all
dosimeters. Nevertheless, wastes and patient urine had to be properly managed
as radioactive wastes, as required by the italian law.
Finally the dose received by the patient was estimated using the OLINDA
program, following the results in Ref. [16]. The total effective dose is 100± 70 mSv.
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The major involved organs are kidneys, spleen and urinary bladder that receives
an absorbed dose of 0.8, 2.1 and 0.8 Gy, respectively. The contribution to the
urinary bladder can be reduced significantly if the patient is catheterized after
injection, which is easily the case for a patient that has to undergo surgical
intervention. In this case the effective dose is reduced to ∼70 mSv. The patient
received the kidney protection (aminoacid solution) used in Peptide receptor
radionuclide therapy (PRRT) trials.
DISCUSSION
Although a single patient is not statistically sufficient to drive conclusions on
the medical efficacy of a technique, a lot of information can be obtained from
the first patient to which this novel approach was applied.
The first information is that the method of assessment of signals in the
probe starting from PET scans with 68Ga-DOTATOC is reliable at the 10-20%
level. This is indeed the level of agreement of the predictions close to the skin
and on the tumor bulk. This assessment strengthens the feasibility studies on
meningioma, glioma and neuro-endocrine tumors already published [9, 10].
Another important confirmation gained from this test is that blood carries
very little radio-tracer, and therefore its presence in the field where the remnants
are searched for and on the probe itself would not alter the results. A different
result would have been a show-stopper for this technique.
As far as the sensitivity to tumor residuals is concerned, the measurements on
the small samples show that, albeit reduced, also a volume of 0.2 ml of residual
would yield a signal that could be clearly discriminated from the background
(∼30 cps vs 1 cps). Actually the signal discrimination is much higher than
needed, even for a fast detection. It will be therefore possible to apply this
technique with a much lower administration than the 4 MBq/kg of patient used
this time.
As far as the predictions are concerned, the reduction in rate from the bulk
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tumor to the small residuals is hard to simulate because it is difficult to estimate
how the application of the probe on the sample modifies its shape and thickness.
In the next tests this will have to be taken care of.
The comparison with results from the histology confirm that all the samples
identified by the probe as malignant were actually of tumor tissue. The probe
also exhibited the expected response to the tumoral infiltration of the dura,
however in this case the signal is small and its identification requires a very
good knowledge of the response to healthy tissues.
Finally, the presumed extremely low level of exposure of the medical per-
sonnel was confirmed while the exposure of the patient is higher than in case
of the conventional diagnostic examinations, due to the long half-life of 90Y.
Nonetheless, it needs to be considered that the patient will undergo only one
treatment with RGS during his life, while potentially several diagnostic scans.
In any case, the aim of these first tests on patient is to minimize the adminis-
tered activity to reduce also the effective dose to the patient. In particular, as
already mentioned, the very positive results of this test allow for a reduction of
at least a factor 3 in activity, if not more. Further developments of the probe
from the light collection and electronics points of view, can further increase its
sensitivity, by lowering the minimum detected energy. Finally, the use of radio-
isotopes with a shorter half-life, which is also under study, would reduce the
dose for a given administered activity.
CONCLUSION
The first test on patient of the radio-guided surgery technique with β−-emitting
radio-tracers proved that administering 4MBq/kg of 90Y-DOTATOC in a pa-
tient affected by meningioma, induced on the β− probe a signal that allows to
discriminate very strongly between tumor and nearby healthy tissues. This is
a fundamental proof of principle to demonstrate the feasibility of the technique
since it shows that the whole mechanism, from the bio-distribution to the signal
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detection was correctly estimated in evaluating the potentialities of the tech-
nique. It also confirms the negligible exposure of the medical personnel with
this approach.
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Figure 1: Tested samples extracted from the patients tumor and con-
nected dura. The meaning of the labels is in the text.
Figure 2: Tumor bulk (sample D in the text) and the probing device.
15
Figure 3: Evaluation of the uptake of the Dura Mater. Top: definition of
the lines of projection of the specific activity. Center: profiles of the specific
activities along the chosen lines, from the nearest (Graf1) to the more distant
(Graf10) from the tumor. Bottom: estimated uptake in the Dura Mater (see
text for details) as a function of distance from the nearest plot profile. The
horizontal line corresponds to the specific activity of the healthy brain.16
Figure 4: Expected rate on the Dura Mater (A and E) samples as a function
of the sample thickness, considering the specific activity extracted from pre-
operative PET scan as described in the text. The horizontal line represents the
experimental rate.
Sample V (ml) R(cps) histology description
A 0.38 5.0 Dural tissue dura
infiltered by meningioma
B 0.23 51.5 Transitional meningioma lesion margin (up)
C 0.72 45.0 Transitional meningioma lesion margin (down)
D 4.84 105.0 Transitional meningioma lesion core
E 0.88 3.5 Dural tissue infiltered by meningioma dura
F 0.21 27.7 Transitional meningioma lesion core residual
G 0.39 39.3 Transitional meningioma lesion core residual
with micronecrosis and occasional mitosis
Table 1: Volume (V ), measured rates (R) and result of the histology
for each of the samples extracted from the patient’s tumor.
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